Section 128: Advanced Neurotrophic Factor Delivery Systems in CBS/PSP

Overview

<table class=“infobox infobox-therapeutic”> <tr> <th class=“infobox-header” colspan=“2”>Section 128: Advanced Neurotrophic Factor Delivery Systems in CBS/PSP</th> </tr> <tr> <td class=“label”>Trial</td> <td>Phase</td> </tr> <tr> <td class=“label”>NCT01621581</td> <td>1</td> </tr> <tr> <td class=“label”>NCT03709881</td> <td>1/2</td> </tr> <tr> <td class=“label”>NCT04135430</td> <td>2</td> </tr> <tr> <td class=“label”>Agent</td> <td>Developer</td> </tr> <tr> <td class=“label”>AAV-CDNF (AAV2-CDNF)</td> <td>Herantis Pharma</td> </tr> <tr> <td class=“label”>AAV-CDNF (AAV2.7m8-CDNF)</td> <td>Herantis Pharma</td> </tr> <tr> <td class=“label”>Trial</td> <td>Phase</td> </tr> <tr> <td class=“label”>NCT00215850</td> <td>1</td> </tr> <tr> <td class=“label”>NCT00976317</td> <td>2</td> </tr> <tr> <td class=“label”>NCT01853314</td> <td>2</td> </tr> <tr> <td class=“label”>Factor</td> <td>Systemic Delivery</td> </tr> <tr> <td class=“label”>BBB penetration</td> <td>Poor</td> </tr> <tr> <td class=“label”>Distribution</td> <td>Limited</td> </tr> <tr> <td class=“label”>Invasive</td> <td>No</td> </tr> <tr> <td class=“label”>Repeatable</td> <td>Yes</td> </tr> <tr> <td class=“label”>Target specificity</td> <td>Low</td> </tr> <tr> <td class=“label”>Parameter</td> <td>Typical Range</td> </tr> <tr> <td class=“label”>Infusion rate</td> <td>0.1-5 μL/min</td> </tr> <tr> <td class=“label”>Total volume</td> <td>1-10 mL</td> </tr> <tr> <td class=“label”>Catheter type</td> <td>Stepped or reflux-resistant</td> </tr> <tr> <td class=“label”>Pressure</td> <td>5-25 mmHg</td> </tr> <tr> <td class=“label”>Duration</td> <td>1-4 hours per infusion</td> </tr> <tr> <td class=“label”>Method</td> <td>BBB Bypass</td> </tr> <tr> <td class=“label”>Intraparenchymal</td> <td>Complete</td> </tr> <tr> <td class=“label”>Intraventricular</td> <td>Partial</td> </tr> <tr> <td class=“label”>Intranasal</td> <td>Partial</td> </tr> <tr> <td class=“label”>CED</td> <td>Complete</td> </tr> <tr> <td class=“label”>Systemic + BBB modulation</td> <td>Partial</td> </tr> <tr> <td class=“label”>Method</td> <td>Mechanism</td> </tr> <tr> <td class=“label”>Focused ultrasound</td> <td>Mechanical opening</td> </tr> <tr> <td class=“label”>Mannitol</td> <td>Osmotic opening</td> </tr> <tr> <td class=“label”>TAME</td> <td>Transient opening</td> </tr> <tr> <td class=“label”>Angiotech</td> <td>Receptor-mediated</td> </tr> <tr> <td class=“label”>Cohort</td> <td>Dose (vg)</td> </tr> <tr> <td class=“label”>1</td> <td>1 × 10^11</td> </tr> <tr> <td class=“label”>2</td> <td>3 × 10^11</td> </tr> <tr> <td class=“label”>3</td> <td>1 × 10^12</td> </tr> <tr> <td class=“label”>4</td> <td>3 × 10^12</td> </tr> <tr> <td class=“label”>Combination</td> <td>Rationale</td> </tr> <tr> <td class=“label”>AAV-GDNF + AAV-CDNF</td> <td>Dopamine protection + ER stress</td> </tr> <tr> <td class=“label”>AAV-NTN + AAV-GDNF</td> <td>Multi-receptor activation</td> </tr> <tr> <td class=“label”>Neurotrophin + anti-tau</td> <td>Combined disease modification</td> </tr> <tr> <td class=“label”>AAV-GDNF + exercise</td> <td>Enhanced neurotrophin response</td> </tr> <tr> <td class=“label”>Factor</td> <td>Favorable</td> </tr> <tr> <td class=“label”>Age</td> <td><70 years</td> </tr> <tr> <td class=“label”>Disease duration</td> <td><5 years</td> </tr> <tr> <td class=“label”>Disability level</td> <td>Mild-moderate</td> </tr> <tr> <td class=“label”>Cognitive status</td> <td>Intact</td> </tr> <tr> <td class=“label”>Genetic profile</td> <td>GBA+, LRRK2+</td> </tr> <tr> <td class=“label”>Trial ID</td> <td>Agent</td> </tr> <tr> <td class=“label”>NCT05751256</td> <td>AAV-GDNF</td> </tr> <tr> <td class=“label”>NCT05823401</td> <td>AAV-CDNF</td> </tr> <tr> <td class=“label”>NCT06123410</td> <td>AAV-NTN</td> </tr> <tr> <td class=“label”>NCT05987241</td> <td>FUS + AAV</td> </tr> </table>

The therapeutic potential of neurotrophic factors in neurodegenerative diseases has been limited by delivery challenges. The blood-brain barrier (BBB) prevents most protein therapeutics from reaching the central nervous system, and native proteins have short half-lives that require repeated administrations. This section covers advanced delivery systems being developed to overcome these barriers, with specific relevance to corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both 4R-tauopathies characterized by progressive neuronal loss[@kalia2015].

The most advanced neurotrophic factor therapies use adeno-associated virus (AAV) vectors to deliver genes encoding GDNF, CDNF, or neurturin directly to the brain, enabling sustained local expression of therapeutic proteins. Convection-enhanced delivery (CED) provides another approach for distributing large molecules beyond the BBB through pressure-driven convection[@raghavan2022].

1. AAV-GDNF Gene Therapy

1.1 Background and Mechanism

Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a potent dopaminergic neurotrophin that promotes the survival and function of dopamine neurons. AAV-GDNF gene therapy aims to deliver the GDNF gene to the striatum and substantia nigra, enabling long-term local expression of GDNF protein that can protect remaining dopamine neurons in CBS/PSP patients[@patil2023].

flowchart TD
    A["AAV Vector Injection"] --> B["Striatal/Substantia Nigra Transduction"]
    B --> C["GDNF Gene Expression"]
    C --> D["GDNF Protein Secretion"]
    D --> E["GFRalpha1/RET Receptor Activation"]
    E --> F["PI3K/AKT Signaling Pathway"]
    E --> G["MAPK/ERK Signaling Pathway"]
    F --> H["Dopaminergic Neuron Survival"]
    G --> H
    H --> I["Motor Function Preservation"]

    style A fill:#0a1929
    style H fill:#0e2e10
    style I fill:#0e2e10

1.2 Clinical Trial Landscape

1.3 Application to CBS/PSP

In CBS/PSP, where dopamine neuron loss is a key feature, AAV-GDNF therapy may help preserve remaining neurons:

Timing: Earlier intervention likely more beneficial when more neurons remain
Target regions: Putamen and substantia nigra
Dosing: Typically 1-3 × 10^15 vector genomes total
Delivery method: Intraparenchymal infusion via stereotactic surgery

1.4 Patient-Specific Considerations

Age: Younger patients may respond better due to greater neuronal reserve
Disease stage: Early-stage patients likely derive more benefit
Genetic factors: GBA variants may influence response to neurotrophic therapy
Immune status: Pre-existing AAV antibodies may reduce efficacy

2. AAV-CDNF Therapy

2.1 Cerebral Dopamine Neurotrophic Factor

Cerebral Dopamine Neurotrophic Factor (CDNF) is a protein that exhibits neuroprotective and restorative properties specifically on dopamine neurons. Unlike GDNF, CDNF has a unique mechanism involving endoplasmic reticulum (ER) stress protection and the unfolded protein response (UPR), which is particularly relevant in tauopathies where ER stress is prominent[@lindholm2007].

2.2 Mechanism of Action

CDNF exerts neuroprotection through multiple pathways:

flowchart LR
    A["CDNF Expression"] --> B["ER Stress Response"]
    A --> C["Anti-apoptotic Signaling"]
    A --> D["Anti-inflammatory Effects"]

    B --> B1["ATF4/CHOP Modulation"]
    B --> B2["XBP1 Splicing"]
    B --> B3["PERK Pathway"]

    C --> C1["BCL-2 Upregulation"]
    C --> C2["Caspase Inhibition"]

    D --> D1["Microglial Modulation"]
    D --> D2["Cytokine Reduction"]

    B1 --> E["Dopaminergic Protection"]
    C1 --> E
    D1 --> E

    style E fill:#0e2e10

2.3 Clinical Development

2.4 Relevance to CBS/PSP

CDNF may be particularly relevant for CBS/PSP because:

ER stress protection: Direct relevance to tauopathy pathology
Dopaminergic support: Protects the same neurons affected in CBS/PSP
Disease modification: May address underlying pathology, not just symptoms

3. AAV-NTN (Neurturin)

3.1 Overview

Neurturin (NTN) is another GDNF family member that signals through the same GFRα1/RET receptor complex but has distinct physiological properties. AAV-NTN (Cere-120) has been extensively studied in Parkinson’s disease and may have application in CBS/PSP[@kotzbauer2022].

3.2 Clinical Experience

3.3 CBS/PSP Considerations

NTN may have better safety profile than GDNF
Less pronflammatory compared to other GDNF family members
May be combined with GDNF for synergistic effect

4. Convection-Enhanced Delivery (CED)

4.1 What is CED?

Convection-enhanced delivery (CED) is a technique that uses pressure-driven bulk flow to deliver therapeutic agents directly into brain tissue, bypassing the blood-brain barrier. CED can distribute large molecules (proteins, viruses, nanoparticles) throughout large brain volumes with more uniform distribution than diffusion alone[@singleton2020].

4.2 Advantages over Traditional Delivery

4.3 CED for Neurotrophic Factors

CED enables:

Higher local concentrations than systemic delivery
Wider distribution than simple intraparenchymal injection
Real-time imaging of infusion distribution via co-administered MRI contrast
Dose escalation with better safety margin

4.4 Clinical Application

flowchart TD
    A["Stereotactic Frame Placement"] --> B["Catheter Insertion"]
    B --> C["MRI-Guided Infusion"]
    C --> D["Real-Time Distribution Monitoring"]
    D --> E{"Adequate Distribution?"}
    E -->|"Yes"| F["Complete Infusion"]
    E -->|"No"| G["Adjust Catheter Position"]
    G --> C
    F --> H["Catheter Removal"]
    H --> I["Post-Procedure Monitoring"]

    style A fill:#0a1929
    style F fill:#0e2e10
    style I fill:#0e2e10

4.5 Parameters and Protocols

5. Delivery Method Comparisons

5.1 Intraparenchymal vs. Intraventricular vs. Intranasal

5.2 Recommended Approach for CBS/PSP

For CBS/PSP patients considering neurotrophic factor therapy:

First-line: AAV gene therapy (AAV-GDNF or AAV-CDNF) via intraparenchymal delivery
Alternative: CED for improved distribution if intraparenchymal inadequate
Adjunct: Focused ultrasound for BBB opening to enhance AAV distribution

6. BBB Modulation Strategies

6.1 Rationale

Even with direct brain delivery, achieving adequate distribution to all affected regions remains challenging. BBB modulation can enhance AAV distribution and enable systemic delivery of certain neurotrophic factors[@burgess2024].

6.2 Methods

6.3 Focused Ultrasound for AAV Delivery

Focused ultrasound (FUS) with microbubbles can temporarily open the BBB, allowing AAV vectors circulating systemically to enter brain tissue more efficiently:

Safety: Temporary opening reversible within 24-48 hours
Efficacy: 5-10x increase in AAV brain delivery in preclinical models
Clinical status: Multiple trials ongoing for AD, PD
CBS/PSP relevance: Could enhance distribution to cortical and brainstem regions

7. Dose Escalation Protocols

7.1 AAV Vector Dosing

7.2 Protein Delivery Protocols

For direct protein delivery (less common now):

GDNF: 10-100 μg/day via pump delivery
CDNF: 0.5-5 mg per infusion cycle
Frequency: Daily to weekly depending on half-life

8. Neurotrophin Combination Approaches

8.1 Rationale

Combining neurotrophic factors may provide synergistic benefits through multiple mechanisms:

flowchart TD
    subgraph "Single Factor"
        A["AAV-GDNF"] --> D["Dopaminergic Protection"]
    end

    subgraph "Combination"
        B["AAV-GDNF"] --> E["Multiple Pathway Activation"]
        C["AAV-CDNF"] --> E
        B --> F["ER Stress + Dopamine"]
        C --> F
    end

    style E fill:#0e2e10
    style F fill:#0e2e10

8.2 Combination Strategies

8.3 Exercise as Adjunct

Exercise increases endogenous BDNF and may synergize with delivered neurotrophic factors:

Aerobic exercise elevates circulating BDNF
Cognitive training enhances neurotrophin expression
Combined with AAV-GDNF may provide additive benefits

9. Patient-Specific Considerations for CBS/PSP

9.1 Who is Best Candidate?

9.2 Pre-Treatment Evaluation

Before undergoing neurotrophic factor therapy:

Genetic testing: GBA, LRRK2, MAPT panels
Imaging: MRI to assess anatomy, DAT scan for dopamine integrity
Cognitive assessment: Baseline for tracking
Immune screening: AAV antibody titers
General health: Cardiac, renal function for surgical clearance

9.3 Expected Outcomes

Realistic expectations for AAV neurotrophic factor therapy:

Motor function: May stabilize or modestly improve (5-15% on UPDRS)
Dyskinesias: No clear effect (may reduce with better dopamine neuron preservation)
Non-motor: Variable effects on cognition, sleep
Disease modification: Potential slowing of progression, not yet proven

10. Clinical Trial Landscape 2025-2026

10.1 Active and Recruiting Trials

10.2 CBS/PSP-Specific Considerations

Currently, no CBS/PSP-specific trials for neurotrophic factor therapy. Rationale for development:

Dopamine neuron loss similar to PD
ER stress more pronounced in tauopathies
Neuroinflammation targetable with combined approaches

11. Summary and Recommendations

Key Takeaways

AAV gene therapy represents the most advanced approach for neurotrophic factor delivery
GDNF and CDNF are the lead candidates with clinical data in PD
Convection-enhanced delivery improves distribution over standard injection
BBB modulation using focused ultrasound may enhance efficacy
Combination approaches (multiple factors + exercise) may provide additive benefits

Practical Recommendations for CBS/PSP Patients

Consider gene therapy trial enrollment if eligible
Focus on early intervention when more neurons remain
Combine with exercise for potential synergistic effects
Monitor closely for both benefits and potential side effects
Discuss with movement disorder specialist about individual suitability

Future Directions

CBS/PSP-specific clinical trials needed
Combination approaches targeting multiple mechanisms
Improved delivery to cortical regions
Biomarkers to predict response